GNPX GENPREX INC Expansion Plans 8-K Filing 2025 - Product Expansion On May 7, 2025, Genprex, Inc. announced a new research agreement for preclinical studies of its diabetes gene therapy GPX-002, which showed promising results in animals, indicating potential treatment benefits for Type 1 and Type 2 diabetes.Get access to all SEC 8-K filings of the GENPREX INC